2016

This is an evolving guide with emerging information on how to clear viral and vaccine-induced spike proteins from the body.

A New York-based, multi-institutional research team has found high levels of three toxic metabolites produced by gut bacteria in the cerebrospinal fluid and plasma samples of multiple sclerosis (MS) patients. The important findings further scientists' understanding of how gut bacteria can impact the course of neurological diseases by producing compounds that are toxic to nerve cells.

Let’s unpack a unique compilation of supplements and explore not just the value of each component and how they work synergistically to lower uric acid.

The recent COVID-19 pandemic is a treatment challenge in the acute infection stage but the recognition of chronic COVID-19 symptoms termed post-acute sequelae SARS-CoV-2 infection (PASC) may affect up to 30% of all infected individuals. The underlying mechanism and source of this distinct immunologic condition three months or more after initial infection remains elusive. Here, we investigated the presence of SARS-CoV-2 S1 protein in 46 individuals. We analyzed T-cell, B-cell, and monocytic subsets in both severe COVID-19 patients and in patients with post-acute sequelae of COVID-19 (PASC). The levels of both intermediate (CD14+, CD16+) and non-classical monocyte (CD14Lo, CD16+) were significantly elevated in PASC patients up to 15 months post-acute infection compared to healthy controls (P=0.002 and P=0.01, respectively). A statistically significant number of non-classical monocytes contained SARS-CoV-2 S1 protein in both severe (P=0.004) and PASC patients (P=0.02) out to 15 months post-infection. Non-classical monocytes were sorted from PASC patients using flow cytometric sorting and the SARS-CoV-2 S1 protein was confirmed by mass spectrometry. Cells from 4 out of 11 severe COVID-19 patients and 1 out of 26 also contained SARS-CoV-2 RNA. Non-classical monocytes are capable of causing inflammation throughout the body in response to fractalkine/CX3CL1 and RANTES/CCR5. Summary SARS CoV-2 S1 Protein in CD16+ Monocytes In PASC ### Competing Interest Statement B.K.P, A.P., H.R., E.L, and EBF. are employees of IncellDx

Nature - People who recover from mild COVID-19 have bone-marrow cells that can churn out antibodies for decades, although viral variants could dampen some of the protection they offer.

Investigation and Prosecution of Those Individuals Responsible for Crimes Against Humanity   29 September 2021     The International Criminal Court Office of the Prosecutor Post Office Box 19519 2500 CM The Hague The Netherlands     And   Ms. Karen Mosoti, or official replacement for the office of Liaison Office of the International Criminal Court to the United Nations 866 United Nations Plaza Suite 476 New York, NY, 10017 USA 212-486-1346/47/62     Email: otp.informationdesk@icc-cpi.int   Dear

By Dr. Mike Williams21stcenturywire.com In prior articles we discussed the increased risk of SARS-COV-2 infection after Covid vaccination and introduced concepts of immune tolerance and immune training. In this article I want to introduce the topic of cellular senescence, specifically as it relates to Covid vaccination. From Cellular Senescence: What, Why, and How we learn: Cellular senescence is a process […]

e-Sword is a feature rich and user friendly free Windows app with everything needed to study the Bible in an enjoyable and enriching manner!

(NaturalHealth365) New Swedish study raises red flags about COVID jab deaths, shows people dying at alarming rates.

(NaturalHealth365) Headline of a recently published Forbes article claiming that mRNA injections alter human DNA triggers massive backlash.

Methods: Open-label, multicenter, retrospective, noncontrolled analysis of long-term visual acuity and safety in 111 LHON patients treated with idebenone (900 mg/day) in an expanded access program. Eligible patients had a confirmed mitochondrial DNA mutation and had experienced the onset of symptoms (most recent eye) within 1 year before enrollment. Data on visual acuity and adverse events were collected as per normal clinical practice. Efficacy was assessed as the proportion of patients with either a clinically relevant recovery (CRR) or a clinically relevant stabilization (CRS) of visual acuity. In the case of CRR, time to and magnitude of recovery over the course of time were also assessed. Results: At time of analysis, 87 patients had provided longitudinal efficacy data. Average treatment duration was 25.6 months. CRR was observed in 46.0% of patients. Analysis of treatment effect by duration showed that the proportion of patients with recovery and the magnitude of recovery increased with treatment duration. Average gain in best-corrected visual acuity for responders was 0.72 logarithm of the minimal angle of resolution (logMAR), equivalent to more than 7 lines on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart. Furthermore, 50% of patients who had a visual acuity below 1.0 logMAR in at least one eye at initiation of treatment successfully maintained their vision below this threshold by last observation. Idebenone was well tolerated, with most adverse events classified as minor. Conclusions: These data demonstrate the benefit of idebenone treatment in recovering lost vision and maintaining good residual vision in a real-world setting. Together, these findings indicate that idebenone treatment should be initiated early and be maintained more than 24 months to maximize efficacy. Safety results were consistent with the known safety profile of idebenone....

David Martin specialises in putting humanity back into humans - and business. David's secret of success globally is ‘The Wobble Effect’. Read more...

Click here to download the document as a PDF

welcome everyone we love you!

medRxiv - The Preprint Server for Health Sciences

A Mississippi doctor said he was fired for attempting to treat COVID-19 patients with ivermectin, which is approved ...

(NaturalHealth365) Mounting evidence shows concerning trends about COVID jab-related health problems, such as a rise in ovarian cancer rates.

Magnesium exhibits a range of neuronal and vascular actions that may ameliorate ischaemic CNS insults, including stroke. Significant neuroprotection with magnesium has been observed in different models of focal cerebral ischaemia in many laboratories, with infarct volume reductions between 25 and 61 …

Pandemic, epidemic, or a medical emergency. No matter what we call it, people suffering from vascular disease have dramatically increased, and too many are dying from it. Not only is there no vaccine possible for heart disease, but in all probability, the COVID vaccines are driving the pain, suffering, and death through sudden onset heart... View Article

Scientific Reports - Weeklong improved colour contrasts sensitivity...

(NaturalHealth365) A U.S. Federal District Judge ruled that the EUA version of the Pfizer shot is not interchangeable with Comirnaty.

Background: Rheumatoid arthritis is a chronic inflammatory disease of autoimmune etiology. Current treatment includes non-steroidal anti-inflammatory drugs, selective cyclooxygenase-2 inhibitors, glucocorticoids, and disease-modifying antirheumatoid drugs, newer agents such as tumor necrosis factor-α inhibitors, and monoclonal antibodies have adverse effects such as peptic ulcer, renal toxicity, and hematological toxicity. Moreover, they are expensive when used on a long-term basis. Hence, it is necessary to find out the new cost effective as well as less toxic drug as alternative. Aim and Objective: The present study was taken up to evaluate antiarthritic activity of Aloe vera aqueous extract (AVE) in Wistar albino rats when used orally. Materials and Methods: A total 36 no. of healthy Wistar albino rats of weight 100–200 mg were used and divided into six different groups containing six rats in each. Into subplantar region of hind paw of all rats except normal control, 0.1 mL of complete Freund’s adjuvant (6 mg Mycobacterium butyricum suspended in heavy paraffin oil) was injected for induction of arthritis. The rats were treated with vehicle (gum acacia), standard drugs (indomethacin and dexamethasone) and test drug, that is, AVE 125 mg/kg, 250 mg/kg for 12 days. The rats were evaluated by measuring the % increase in paw edema volume and paw thickness (joint diameter), assessing the biophysical parameters (arthritic score), hematological parameters erythrocyte sedimentation rate, rheumatoid factor, and histopathological study of joints (arthritic index) for testing the antiarthritic potential. Results: AVE 250 mg/kg showed significant antiarthritic property as that of standard indomethacin and dexamethasone in terms of reduction in inflammation and arthritic scores. Conclusion: AVE at 250 mg/kg offered significant protection against arthritis and inflammation and can be a safer alternative for long term use.

Covid Care At Synergy Health DPC, our goal is to keep you healthy at home Should you or any of your family seek to prevent becoming ill with Covid, experience the common symptoms of Covid or have lingering effects of Post Covid Syndrome, please be assured that we offer several different Covid protocol options that… Continue reading Covid Care

We provide affordable concierge TeleHealth visits to all of our patients ages 12 and up. Our providers often can schedule an acute care visit with limited wait times. We also offer specialized services to address dementia, fibromyalgia and other long term conditions. Additionally, we are available as a health advocate should you or a loved one need hospital or specialist care

It's Time to Get Factsinated, with short video content featuring experts delivering facts about Covid-19, Vaccines, and Pharmaceutical drugs.